Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NQO1 | P15559 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL94221 | 0.86 | POLB (0.42) | MAPTALDH1A1KDM4EGAAPOLB | |
| Alcohol SCHEMBL2594726 | 0.78 | GAA (0.43) | MAPTALDH1A1KDM4EGAAPOLB | |
| SCHEMBL14071570 | 0.76 | POLB (0.38) | MAPTALDH1A1KDM4EGAAPOLB | |
| SCHEMBL16575414 | 0.74 | NQO1 (0.40) | ALDH1A1KDM4ETSHRHSD17B10NQO1 | |
| SCHEMBL1671594 | 0.72 | GAA (0.43) | MAPTALDH1A1KDM4EGAAPOLB | |
| SCHEMBL709314 | 0.72 | GAA (0.36) | MAPTALDH1A1KDM4EGAAPOLB | |
| SCHEMBL8239351 | 0.72 | POLB (0.36) | MAPTALDH1A1KDM4EGAAPOLB | |
| Lithium Ion SCHEMBL5016662 | 0.70 | POLB (0.35) | MAPTGAAPOLBTSHR | |
| SCHEMBL14518584 | 0.70 | GAA (0.42) | MAPTGAAPOLBTSHRLMNA | |
| SCHEMBL2443496 | 0.70 | POLB (0.35) | MAPTALDH1A1GAAPOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-117229281-A | Di-parallel ring derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-12-15 | — | — | CN | disclosed |
| US-11820759-B2 | Modulators of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230227428-A1 | AMIDO COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| EP-3087077-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20180141934-A1 | MODULATORS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. | 2018-05-24 | — | — | US | disclosed |
| US-20180066006-A1 | E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GLYCOMIMETICS, INC. (US) | 2018-03-08 | — | — | US | disclosed |
| US-9867841-B2 | Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells | GLYCOMIMETICS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9839629-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2017-12-12 | — | — | US | disclosed |
| US-9839629-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20110213029-A1 | 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands | SCHERING CORPORATION (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110201794-A1 | Disaccharides for drug discovery | ALCHEMIA LIMITED (AU) | 2011-08-18 | — | — | US | disclosed |
| US-20110160469-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS | MERCK SHARP & DOHME LLC | 2011-06-30 | — | — | US | disclosed |
| EP-2305695-A2 | Macrocyclic inhibitors of Hepatitis C virus replication | Intermune, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305697-A2 | Macrocyclic inhibitors of Hepatitis C virus replication | Intermune, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305698-A2 | Macrocyclic inhibitors of Hepatitis C virus replication | Intermune, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305696-A2 | Macrocyclic inhibitors of Hepatitis C virus replication | Intermune, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| US-20110009482-A1 | METHODS OF TREATING COPD | SCHERING CORPORATION (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100022579-A1 | SUBSTITUTED TETRAHYDROQUINOLINES | Merck Patent Gesellschaft mit bescrankter Haftung (DE) | 2010-01-28 | — | — | US | disclosed |
| EP-2103623-A2 | Novel macrocyclic inhibitors of Hepatitis C virus replication | Intermune, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160469-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS | CCL2, CCR1, CXCR1 | MAPT 4588/4885ALDH1A1 1721/4885KDM4E 4463/4885 |
| US-20110213029-A1 | 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands | CCR1, ACKR3, CXCR1 | MAPT 4618/4885ALDH1A1 1019/4885KDM4E 4760/4885 |
| US-20110201794-A1 | Disaccharides for drug discovery | UGCG, STT3A, DDOST | MAPT 1245/4885ALDH1A1 2021/4885KDM4E 3586/4885 |
| US-20230227428-A1 | AMIDO COMPOUNDS | RIPK1, RIPK3, MLKL | MAPT 266/4885ALDH1A1 4812/4885KDM4E 3134/4885 |
| US-11820759-B2 | Modulators of chemokine receptors | CCR5, CXCR3, CCR2 | MAPT 4650/4885ALDH1A1 3679/4885KDM4E 4657/4885 |
| US-20110009482-A1 | METHODS OF TREATING COPD | CXCR2, AGTR2, LTB4R2 | MAPT 4716/4885ALDH1A1 430/4885KDM4E 3847/4885 |
| US-20180141934-A1 | MODULATORS OF CHEMOKINE RECEPTORS | CCR5, CXCR3, CCR2 | MAPT 4650/4885ALDH1A1 3679/4885KDM4E 4657/4885 |
| US-20180066006-A1 | E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SELE, SELPLG, SELP | MAPT 3239/4885ALDH1A1 3541/4885KDM4E 3628/4885 |
| US-20100022579-A1 | SUBSTITUTED TETRAHYDROQUINOLINES | RECQL, NDUFS3, TPD52L2 | MAPT 3974/4885ALDH1A1 1828/4885KDM4E 1089/4885 |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | MAPT 2444/4885ALDH1A1 3906/4885KDM4E 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.